Cairo – Mubasher: Ibnsina Pharma announced the completion of procedures for the establishment of a new investment firm with an authorised capital of EGP 750 million.
The issued capital of the new company, in which Ibnsina Pharma will hold 99%, is planned to stand at EGP 300 million, according to a bourse disclosure on Monday.
The new company will invest and enter into partnerships in the financial technology and digital transformation of the healthcare sector, along with the provision of logistics services.
In 2020, the pharmaceutical company reported consolidated net profits of EGP 224.66 million, down from EGP 328.77 million a year earlier, including minority shareholders’ rights.
